Mesoblast (MESO) Company Gross Revenue

Mesoblast Limited (MESO) is implementing allogeneic cell therapies, although global political tensions are complicating the international logistics of biomaterials. The company's sold goods on this chart allow for a comparison of actual revenue against management's plans, where 0.12 serves as the base parameter value. Personnel stability and the retention of rare experts through stock options guarantee the successful development of long-term R&D projects.

MESO Mesoblast Pharma: Revenue and Sales Volume in the range 07/04/2022 - 11/15/2026

Comprehensive metric breakdowns and analytics for Mesoblast Ltd (MESO)

- market price and analyst price targets:

Market Price mesoblast.com|MESO - Price Target Chart

- market capitalization details:

Market Capitalization Mesoblast Corp|MESO - Total Company Value

- book capitalization data:

Net Asset Value per Share Mesoblast|MESO - Book Capitalization|Market Value to Book Value Ratio mesoblast.com|MESO - Aggregate Company Assets

- company liabilities and liquidity data:

- business earnings and investment ratios data:

MESO - Company Net Income|Expected Profit Mesoblast Limited|MESO - P/E Multiple|Market Cap to Projected Earnings Mesoblast Ltd|MESO - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Mesoblast Ltd|MESO - Operating profit EBITDA|Net earnings per share for the last four quarters Mesoblast|MESO - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months mesoblast.com|MESO - Earnings growth in current year|Expected net earnings per share growth next year Mesoblast Limited

- company sales and revenue statistics:

MESO - Revenue and Sales Volume|Company Revenue Forecast mesoblast.com|MESO - Price-to-Revenue Ratio|Forward Price-to-Revenue Multiple Mesoblast Ltd|MESO - Sales Growth YoY (TTM)

Comprehensive company analysis:Mesoblast Limited

The stable technological barrier of Mesoblast Limited (MESO), based on cell therapy patents, ensures business resilience during periods of regulatory reviews. Monitoring actual cash inflows through changes in the company's sales volume allows for the filtering of market noise to assess real liquidity, where stable values confirm the viability of the model, while a decline warns of the risk of capital freezing.

Competing companies